

AGOMAB THERAPEUTICS NV

Posthoflei 1 box 6
2600 Antwerpen (Berchem)
Company number: 0674.527.310
RLE Antwerp, section Antwerp
(The “Company”)

Minutes of the Annual General Meeting of Shareholders held on May 26, 2026 in Antwerp (Berchem)

The Annual General Meeting of Shareholders will be held at the Company’s registered office and will commence at 16:00 (CEST).

Composition of the Bureau

In accordance with the Articles of Association, the Bureau is composed as follows:

- In the absence of the Chair of the Board of Directors, Mr Tim Knotnerus is appointed as Chair of the meeting.
- Ms Ellen Lefever is appointed by the Chair as secretary.
- Given the limited number of attendees, no tellers are appointed.

Convening formalities

The Chair notes that all holders of securities issued by the Company, the statutory auditor and Mr Ohad Hammer, in his capacity as a director, were convened by email on April 24, 2026. The other directors of the Company waived the notice requirements for this meeting during the meeting of the Company’s Board of Directors on April 17, 2026. The statutory auditor also waived the notice requirements for this meeting by letter dated May 19, 2026.

The convening notice of the meeting and the accompanying documents were also made available as from April 24, 2026 on the Company’s website (<https://ir.agomab.com/governance/shareholder-meetings>).

Given that the Company’s ordinary shares and subscription rights are all issued in registered form, the Chair notes that the meeting was convened in accordance with Article 7:127 of the Companies and Associations Code of March 23, 2019 (as amended from time to time) (the “CAC”)

Holders of American Depositary Shares (“ADSs”) of the Company received the necessary information, documents and instructions relating to this Annual General Meeting from The Bank of New York Mellon, in its capacity as depository, or from the broker, bank or other nominee with whom the holder holds their ADSs.

Attendance

The Chair explains that the shareholders, whose identities, addresses and the number of shares held by them as at the record date (being May 19, 2026 at 00:00 CEST) are listed in the attached attendance list (Annex 1), are present, are represented or have cast their votes by voting form.

This attendance list was signed by the shareholders present or their proxyholders at the start of the meeting. At the same time, the Bureau verified their identities, the proxies and the voting forms. The proxies and voting forms are attached to these minutes (Annex 2 and Annex 3). All proxies and voting forms were received by the notification deadline, being May 20, 2026 at 23:59 (CEST), and are recognized as valid by the Bureau.

Quorum

No quorum is required for this meeting in accordance with the CAC and the Articles of Association. The meeting may therefore validly deliberate and pass resolutions, regardless of the number of shares present and/or represented.

The Chair confirms that the Company's share capital is currently represented by 49,247,975 shares, of which 33,363,395 shares (67.75% of the share capital) are present or represented at the meeting, as shown in the attendance list.

Voting rights and majority

Each share in the Company entitles the holder to one vote. Any proposed resolution is validly adopted if it secures a simple majority of the votes cast, in accordance with the CAC and the Articles of Association.

Agenda

The Chair explains that this meeting is convened with following agenda and proposed resolutions:

1. For information purposes only, acknowledgement and discussion of the consolidated financial statements prepared (on a voluntary basis) in accordance with International Financial Reporting Standards, and additional related information and explanations, for the financial year ended December 31, 2025.
2. Acknowledgement and discussion of the statutory financial statements, the report of the Board of Directors and the statutory auditor's report for the financial year ended December 31, 2025.
3. Approval of the statutory financial statements for the financial year ended December 31, 2025 and of the allocation of the result as proposed by the Board of Directors.
Proposed resolution: The general meeting resolves to approve the statutory financial statements for the financial year ended December 31, 2025 and of the allocation of the result as proposed by the Board of Directors.
4. Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025, as well as discharge for failing to hold the annual general meeting in the year 2025 on the date specified in the articles of association.
Proposed resolution: The general meeting grants discharge to each current and former director, including the former director Xiaoming Fang who resigned with effect from January 16, 2026, and the statutory auditor, for all liability arising from the exercise of their respective mandates during the financial year ended December 31, 2025. The general meeting also grants discharge to each current and former director for failing to hold the annual general meeting in

the year 2025 on the date specified in the articles of association.

5. Reappointment of Mr. Ohad Hammer as a member of the Board of Directors.
Proposed resolution: As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the general meeting resolves to reappoint Mr. Ohad Hammer, who elects domicile at the Company's registered office, as a director for a term of one year ending immediately after the annual general meeting to be held in 2027. Mr. Ohad Hammer's mandate is remunerated. For the performance and duration of his mandate, Mr. Hammer is entitled to the annual remuneration as approved by the extraordinary general meeting of shareholders of the Company on January 15, 2026 and as determined in the notarial deed of February 9, 2026.
6. Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors.
Proposed resolution: As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the general meeting resolves to reappoint Mr. Tim Knotnerus, who elects domicile at the Company's registered office, as a director for a term of four years ending immediately after the annual general meeting to be held in 2030. Mr. Tim Knotnerus' mandate as director is unpaid.
7. Determination of statutory auditor's fee.
Proposed resolution: As proposed by the Company's audit committee, the general meeting resolves to approve, and insofar as necessary, ratify the increase of the statutory auditor's fee to EUR 237,530 for the audit of the statutory financial statements and the consolidated financial statements for the financial year ended December 31, 2025 and the financial year ending on December 31, 2026. This amount is exclusive of various expenses, the IRE/IRB fee and VAT and is subject to indexation for financial year 2026.

The Bureau confirms that no written questions have been received regarding the agenda set out above.

Deliberations and decisions

The general meeting confirms that the above statements are correct, that it has been validly convened and composed, and that it is therefore entitled to deliberate and vote on the aforementioned agenda items.

The general meeting proceeds with the agenda as set out below.

First agenda item

The general meeting acknowledges and discusses the consolidated financial statements prepared (on a voluntary basis) in accordance with International Financial Reporting Standards, together with the additional related information and explanations, for the financial year ended December 31, 2025.

No vote is required on this agenda item.

Second agenda item

The general meeting acknowledges and discusses the draft statutory financial statements, the report of the Board of Directors, and the statutory auditor's report for the financial year ended December 31, 2025.

No vote is required on this agenda item.

Third agenda item

The general meeting resolves to approve the statutory financial statements for the financial year ended December 31, 2025 and of the allocation of the result as proposed by the Board of Directors

This resolution is adopted by the general meeting with 33,363,366 votes for (99.99%), no votes against and 29 abstentions.

Fourth agenda item

The general meeting grants discharge to each current and former director, including the former director Xiaoming Fang who resigned with effect from January 16, 2026, and the statutory auditor, for all liability arising from the exercise of their respective mandates during the financial year ended December 31, 2025. The general meeting also grants discharge to each current and former director for failing to hold the annual general meeting in the year 2025 on the date specified in the articles of association.

This resolution is adopted by the general meeting with 33,363,307 votes for (99.99%), 86 votes against and 2 abstentions.

Fifth agenda item

As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the general meeting resolves to reappoint Mr. Ohad Hammer, who elects domicile at the Company's registered office, as a director for a term of one year ending immediately after the annual general meeting to be held in 2027. Mr. Ohad Hammer's mandate is remunerated. For the performance and duration of his mandate, Mr. Hammer is entitled to the annual remuneration as approved by the extraordinary general meeting of shareholders of the Company on January 15, 2026 and as determined in the notarial deed of February 9, 2026.

This resolution is adopted by the general meeting with 33,363,208 votes for (99.99%), 8 votes against and 179 abstentions.

Sixth agenda item

As proposed by the Board of Directors and in accordance with the recommendation of the Company's remuneration, nomination and corporate governance committee, the general meeting resolves to reappoint Mr. Tim Knotnerus, who elects domicile at the Company's registered office, as a director for a term of four years ending immediately after the annual general meeting to be held in 2030. Mr. Tim Knotnerus' mandate as director is unpaid.

This resolution is adopted by the meeting with 33,363,207 votes for (99.99%), 8 votes against and 180 abstentions.

Seventh agenda item

As proposed by the Company's audit committee, the general meeting resolves to approve, and insofar as necessary, ratify the increase of the statutory auditor's fee to EUR 237,530 for the audit of the statutory financial statements and the consolidated financial statements for the financial year ended December 31, 2025 and the financial year ending on December 31, 2026. This amount is exclusive of various expenses, the IRE/IRB fee and VAT and is subject to indexation for financial year 2026.

This resolution is adopted by the general meeting with 33,363,216 votes for (99.99%), no votes against and 179 abstentions.

Closure of the meeting

Having dealt with all items on the agenda, the Chair declared the meeting closed at 16:15 CEST. These minutes were drawn up at the place and date stated above and, following approval by the meeting, were signed by the members of the bureau.

These minutes for the annual general meeting has been drawn up in Dutch. The English free translation is provided for information purposes only. In the event of any discrepancies or differences in interpretation between the two versions, the Dutch version shall always take precedence.

Tim Knotnerus, voorzitter

Ellen Lefever, secretary
